<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B-cell lines of diverse neoplastic origin express the <z:chebi fb="19" ids="28790">serotonin</z:chebi> transporter (SERT/SLC6A4) and <z:mpath ids='MPATH_73'>growth arrest</z:mpath> in response to SERT-ligands, including the antidepressants chlomipramine and <z:chebi fb="0" ids="5118">fluoxetine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we detail SLC6A4 transcript (Q-PCR) and protein (FACS) expression in primary cells from patients with: <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>; mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The ability of the SERT-binding antidepressants to impact the growth of these cells when sustained on CD154-transfected fibroblasts was also determined </plain></SENT>
<SENT sid="3" pm="."><plain>The results reveal a broad spectrum of primary B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> expressing SLC6A4 with a proportion additionally displaying <z:mpath ids='MPATH_73'>growth arrest</z:mpath> on SERT-ligand exposure </plain></SENT>
</text></document>